Introduction
Nivolumab is a recently approved human IgG4 anti-programmed cell death protein-1 (PD-1) monoclonal antibody that works as a checkpoint inhibitor (CPI), augmenting the immune response against tumour cells. Because of this mechanism of action, it has the potential of causing multiple described autoimmune-related events, including cardiac events. 1 However, the real incidence, manifestation, and treatment of cardiac complications remains unclear. We hereby present a case of a patient who developed heart failure and cardiogenic shock after treatment with these agents.
Timeline Case presentation
A 47-year-old woman with a history of carotid artery dissection and metastatic melanoma presented with acute decompensated heart failure. One year prior to presentation, she had received one cycle of combination CPI therapy with ipilimumab and nivolumab. Due to rapidly progressive disease, these medications were discontinued and she was started on dabrafenib and trametinib, BRAF inhibitors. She had initial improvement on this new regimen, and then nivolumab was restarted four months prior to her heart failure presentation.
One month prior to presentation, she developed asymptomatic supraventricular tachycardia and subsequent dyspnoea before hospitalization. On admission, she was afebrile, hypotensive and tachycardic, tachypnoeic, with pulmonary oedema, jugular venous distension, ascites, and lower extremity oedema. Initial ECG demonstrated a regular, narrow-complex rhythm, concerning for atrial tachycardia and without ischaemic changes. Serum troponins were negative, CK was negative, and serum proBNP was 3797 pg/mL (normal reference <300 pg/mL). A transthoracic echocardiogram revealed global 
Learning points
• Nivolumab is a recently approved human IgG4 anti-programmed cell death protein-1 (PD-1) monoclonal antibody that works as a checkpoint inhibitor, augmenting the immune response against tumour cells. Hence, Nivolumab has the potential to affect many organs, including the heart, resulting in an adverse reaction.
• There is not enough data to direct the diagnosis and treatment of patients presenting with myocarditis from checkpoint inhibitors, as the reported incidence of cardiac complications using these agents has likely been underestimated. To highlight the utility of cardiac imaging in this disease state, we present a case of immunotherapy-induced myocarditis with findings on cardiac MRI correlating with areas of myocardial lymphocytic infiltrate and fibrosis on post-mortem pathology.
One year prior to presentation LGE), most consistent with a myocarditis. Given the recent use of nivolumab and the cardiac imaging findings, the diagnosis of immunotherapy-mediated cardiac toxicity was highly considered, and immunosuppressive therapy with steroids (methylprednisolone 500 mg intravenous BID for 5 days) and infliximab (10 mg/kg/day for 2 days) was initiated. Her clinical course was complicated by cardiogenic shock refractory to inotropic support. Due to her poor prognosis, left and right heart catheterization with endomyocardial biopsy and advanced mechanical circulatory support were not pursued. She was palliated and died in the hospital. An autopsy was performed and tissue samples were obtained from areas of myocardium with and without LGE on the CMR. Cardiovascular magnetic resonance imaging was performed on a Siemens 1.5 T scanner. Cine images were acquired with steady state free precession sequences and revealed four-chamber dilation with severe biventricular dysfunction [LVEF 16%; and right ventricular (RV) ejection fraction 12%] (Supplementary material online, Videos S1 and S2). Late gadolinium enhancement-cardiovascular magnetic resonance was performed using 2D single-shot and segmented inversion-recovery sequences, demonstrating mid-wall and epicardial enhancement of the basal to mid-inferior and inferolateral segments, with a focal area of increased signal intensity at the inferior RV insertion site (Figure 1) , involving 15% of the total LV myocardium upon quantitative analysis. Due to the patient's difficulty with breath holds, diagnostic T2 imaging could not be obtained. On microscopy, haematoxylin and eosin (H&E) stains showed evidence of moderate lymphocytic myocarditis in the regions with LGE (Figure 2) , with a mild infiltrate throughout other regions of the heart. The infiltrate was composed almost exclusively of T-cells, with an admixture of CD4þ (helper) and CD8þ (cytotoxic) T-cells. Trichrome stain showed moderate fibrosis in the areas of LGE (Figure 3) . Programmed cell death protein ligand-1 (PD-L1) stain showed focal membrane positivity in the areas of LGE (Figure 4) . No significant coronary artery disease was seen on autopsy.
Discussion
Nivolumab is a recently approved human IgG4 PD-1 monoclonal antibody that works as a CPI, augmenting the immune response against tumour cells. Although these CPIs have revolutionized the treatment of many cancers, they have also been associated with a spectrum of immune-related adverse events, as they also can affect normal cells. 1 It has been described that cardiac complications develop in less than 1% of patients treated with CPIs, with a 0.06% incidence reported in nivolumab specifically, 2 and more recent data have suggested the prevalence of myocarditis was higher at 1.14%. 3 However, the incidence may actually be higher, given the lack of cardiac monitoring during treatment. One possible pathophysiologic mechanism is that cardiac myocytes may share targeted antigens with the tumour, consequently becoming targets of activated T-cells, resulting in lymphocytic infiltration with downstream heart failure and conduction abnormalities. Although not fully understood nor investigated why the troponin was negative in this case, anti-troponin autoantibodies, had they been present, may result in a falsely low serum troponin level. 4 Although the patient did receive other potentially cardiotoxic therapy with BRAF inhibitors, it was felt that the timing of the presentation in regards to initiation of nivolumab and the histology, which was consistent with other published reports of CPI associated myocarditis, most supported nivolumab as the underlying cause. When clinically suspected, echocardiography is usually the initial test for cardiac function. However, CMR offers the additional benefit of tissue characterization for diagnosis of inflammation and fibrosis. The value of CMR for diagnosis and prognosis in myocarditis and other non-ischaemic cardiomyopathies has been well established. 5 The role of CMR in this particular cohort of patients has not yet been elucidated, although it holds great potential for the diagnosis and management of adverse cardiac effects from immunotherapy.
Here, we present a case of immunotherapy-induced myocarditis with LGE on CMR correlating with areas of myocardial lymphocytic infiltrate and fibrosis on post-mortem pathology. Although published cases have reported the use of CMR in suspected immunotherapyinduced myocarditis, this is the first case demonstrating direct histological correlation of T-lymphocytic infiltration with areas of LGE on CMR. Interestingly, although the lymphocytic infiltration was most significant in the areas of LGE, there was still evidence of less severe lymphocytic infiltration in areas without LGE, suggesting a more diffuse inflammatory process. Additionally, the presence of fibrosis in the areas of LGE also raises the possibility of a more subacute component to the cardiotoxicity as well. Future investigation with more sensitive techniques using CMR for early detection of inflammation and left ventricular dysfunction may help to diagnosis disease earlier and guide therapy in these patients.
